MedTrace Logo

Prediction of Aortic Dilatation and Rupture

NCT05065996 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 170

Last updated 2025-08-12

No results posted yet for this study

Summary

Aortic aneurysm is a very common incidental finding in the diagnostic imaging of the chest. It is especially common in middle aged men (up to 40 %). It is called as a silent killer, since it can lead to aortic dissection and rupture without pre-existing symptoms. Mortality of rupture can be up to 50 %. This is why it causes extensive human uncertainty and fear. Currently, there are no methods to identify the high risk patients. That leads to a practice where all patients are followed with repeated aortic imaging using expensive methods such as magnetic resonance imaging (MRI) and computed tomography.

There is data, that modern 4D flow MRI parameters well describe the intra-aortic flow conditions. This prospective clinical trial explore the value of 4D flow MRI parameters in the prediction of aortic dilatation and rupture. The trial consists of three subtrials in whitch the 4D flow MRI parameters are tested in clinical practice.

Conditions

  • Aortic Rupture

Interventions

DIAGNOSTIC_TEST

Aortic MRI + 4D flow MRI

Together with routine aortic MRI specific 4D flow MRI sequence will be done.

Sponsors & Collaborators

  • University of Eastern Finland

    collaborator OTHER

  • JAMK University Of Applied Sciences

    collaborator OTHER

  • Kuopio University Hospital

    lead OTHER

Principal Investigators

  • Marja Hedman, Prof · Kuopio University Hospital

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-01
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • Finland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065996 on ClinicalTrials.gov